DrugPatentWatch Database Preview
OPDIVO Drug Profile
Email this page to a colleague
» See Plans and PricingSummary for Tradename: OPDIVO
| Patents: | 133 |
| Applicants: | 1 |
| BLAs: | 2 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for OPDIVO |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for OPDIVO |
Recent Clinical Trials for OPDIVO
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Pauline Funchain | Phase 2 |
| State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | Phase 2 |
| Merck Serono International SA | Phase 2 |
Recent Litigation for OPDIVO
Identify key patents and potential future biosimilar entrants
PTAB Litigation
| Petitioner | Date |
|---|---|
| Genome & Company | 2018-10-02 |
Pharmacology for OPDIVO
| Mechanism of Action | Programmed Death Receptor-1-directed Antibody Interactions |
Patent Text Search: US Patents for OPDIVO
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | 2035-06-26 | RX | search | |
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | Oncomatryx Biopharma, S.L. (Derio, ES) | 2034-02-06 | RX | search | |
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | Biodesix, Inc. (Boulder, CO) | 2035-07-13 | RX | search | |
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN) | 2034-10-30 | RX | search | |
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2032-08-30 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for OPDIVO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 110172057 | Start Trial |
| Canada | 2841867 | Start Trial |
| Hungary | E040517 | Start Trial |
| Mexico | 2017012738 | Start Trial |
| Russian Federation | 2017112379 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
